ifosfamida libra 1 g polvo liofilizado para solución inyectable infusión i.v.
laboratorio libra, s.a. - ifosfamida - ifosfamida....1.00 g
fosfidex 1g polvo liofilizado para solucion inyectable intravenosa.
laboratorios pisa, s.a. de c.v. - ifosfamida - ifosfamida....1.000 g
holoxan 1g/vial polvo para solución inyectable i.v. por infusión
baxter oncology gmbh - ifosfamida - ifosfamida....1 g
isoxan 1 g. polvo para solucion inyectable i.v.
korea united pharm, inc - ifosfamida - ifosfamida....1g
glimepiride denk 3 tablets
denk pharma gmbh & co. kg - glimepiride - tablets - 3mg
glimepiride denk 2 tablets
denk pharma gmbh & co. kg - glimepiride - tablets - 2mg
glimepiride denk 2 tablets
denk pharma gmbh & co. kg - glimepiride - tablets - 2mg
glimepiride denk 3 tablets
denk pharma gmbh & co. kg - glimepiride - tablets - 3mg
ifosfamide injection
hikma pharmaceuticals usa inc. - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 50 mg in 1 ml - ifosfamide injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. ifosfamide is contraindicated in patients with: • known hypersensitivity to administration of ifosfamide. • urinary outflow obstruction. ifosfamide can cause fetal harm when administered to a pregnant woman. fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo . in pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of gestation. embryo-lethal effects were observed in rats following the administration of 54 mg/m2 doses of ifosfamide from the 6th through the 15th day of gestation